Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Oct 24:13:1065570.
doi: 10.3389/fimmu.2022.1065570. eCollection 2022.

Editorial: Regulatory T lymphocytes in cancer immunity

Dennis Adeegbe  1 , Joseph Barbi  2   3 , James Wing  4
Affiliations
Editorial

Editorial: Regulatory T lymphocytes in cancer immunity

Dennis Adeegbe et al. Front Immunol. .
No abstract available

Keywords: Foxp3 interactome; KLRG1; black raspberries; branched chain amino acid (BCAA); hematologic malignances; regulatory T cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Regulatory T Lymphocytes in Cancer Immunity

Similar articles

See all similar articles

Cited by

References

    1. Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res (2017) 27(1):109–18. doi: 10.1038/cr.2016.151 - DOI - PMC - PubMed
    1. Henson SM, Franzese O, Macaulay R, Libri V, Azevedo RI, Kiani-Alikhan S, et al. . KLRG1 signaling induces defective akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells. Blood (2009) 113(26):6619–28. doi: 10.1182/blood-2009-01-199588 - DOI - PubMed
    1. Wang JM, Cheng YQ, Shi L, Ying RS, Wu XY, Li GY, et al. . KLRG1 negatively regulates natural killer cell functions through the akt pathway in individuals with chronic hepatitis c virus infection. J Virol (2013) 87(21):11626–36. doi: 10.1128/JVI.01515-13 - DOI - PMC - PubMed
    1. Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer (2020) 8(2):1–7. doi: 10.1136/jitc-2020-000957 - DOI - PMC - PubMed
    1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science (2018) 359(6382):1350–5. doi: 10.1126/science.aar4060 - DOI - PMC - PubMed

Publication types

Substances